SLC39A9 and prostate carcinoma: However, potential adverse effects on human health as a consequence of the inhibition of ZIP9-dependent functions could include the attenuation of testosterone-activated pro-apoptotic and antitumorigenic effects in prostate cancer cells [9,12].